Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sysmex Europe, a developer of diagnostic, software and automation products for medical laboratories, and AdnaGen, a privately held biotechnology R&D company, have entered into a non-exclusive European distribution agreement for all current and future AdnaGen CE-certified diagnostics as well as their research use only products.
Subscribe to our email newsletter
The AdnaTest diagnostic and analytical products for breast and colon cancer are aimed at improving cancer prognosis and patient management. The tests are based on immunomagnetic selection of tumor cells from blood followed by detection of tumor specific markers using real-time-polymerase chain reaction (RT-PCR) amplification techniques.
The AdnaTest addresses several clinical needs including: Improvement of determination of disease prognosis, providing insight into which drug targets may be present on metastases, giving rapid feedback on which therapies are providing the desired clinical benefit as well as early detection of disease recurrence, the two companies said.
Alexander Weis, chairman of the supervisory board of AdnaGen, said: “We believe that the combination of the advantages provided by our AdnaGen products and the impressive distribution network of Sysmex will greatly accelerate the commercialization of our products and the reach of Sysmex in the oncology diagnostic and analytical marketplace.”